Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REST-ON trial of once-nightly FT218 in narcolepsy
NL-OMON45892Phase 3Active, not recruiting
- Sponsor
- Avadel Pharmaceuticals
- Start
- Aug 2017
- Modality
- Cell Therapies, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in narcolepsy comparing FT218 with Placebo (2 arms). Primary endpoints: Mean sleep latency on Maintenance of Wakefulness Test, Clinical Global Impression rating of sleepiness and 1 more. Started Aug 2017; status: active, not recruiting.
02
Drugs
AV001
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NL-OMON45892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45892.